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My long association with T.B. Fitzpatrick (TBF) at Portland,
Oregon and Boston, Massachusetts covers a span of 47
years—from 1956 to 2003. This essay fulfillls one of
Fitzpatrick’s quotations by Oliver Wendell Holmes: ‘‘Historic
continuity with the past is not a duty, it is only a necessity’’.
In 1980 TBF told me, ‘‘The Department is built on the
strength and dedicated efforts of its faculty, residents,
fellows and staff of both clinical and basic research. No
stronger foundations can exist than that of trust, respect,
and desire shared by these parties working for advances in
the basic sciences and clinical areas and for the excellent
care of patients’’. He inspired me to work in my research
laboratories and generate additional funds for the science of
skin diseases.
In 1956, after careful evaluation and strong recommen-
dations from his trusted friend Dr Soli Hakim (Oxford
University), TBF invited me to work in his research unit at
the University of Oregon Medical School in Portland, where
he was the chairman and Professor of Dermatology.
Fitzpatrick was fascinated with the melanogenic and suntan
stimulating action of 8-methoxypsoralen (8-MOP), isolated
by chemists from an Egyptian plant (Ammi majus Lin). TBF
was using 8-MOP for repigmenting the amelanotic and
disfiguring skin of vitiligo patients and for treating the
hypopigmented skin of fair-skinned Cuacasians. The re-
search unit at Portland included: Dr Howard Mason, a
professor of Biochemistry working on tyrosinase and
tyrosine and its hydroxylation and subsequent oxidation to
melanin; Dr W.L. Fowlkes, an organic chemist interested in
photochemical interaction of UV radiation and biological
substrates, including the inhibition of mitochondrial en-
zymes and photosensitized lethal inhibition of bacterial
growth; Dr A. Kukita, a dermatologist from the University of
Tokyo Medical School working on melanin pigmentation of
human hair with radio-labeled tyrosine; Dr George Szabo,
an anatomist studying the population density of melano-
cytes of all ethnic varieties of human skin in different regions
of the body.
Having a background in biochemistry and pharmaceu-
tical and medicinal chemistry, with two postgraduate
degrees from Bombay University, I was assigned to work
on furocoumarins (psoralens and isopsoralens) and enrolled
as a PhD student in biochemistry and biophysics on the skin
photosensitizing action and augmentation of melanin
pigmentation. We established that linearly annulated tricyc-
lic furocoumarins (e.g., 8-MOP, 5-MOP, 4,50,8 trimethyl-
psoralen, TMP) and a few other psoralens (over 10) were
uniquely photoactive, inducing phototoxicity and increased
melanin pigmentation of mammalian skin.
Professor M. Seiji of Sendai, Japan collaborated with
TBF at Oregon in 1958, and subsequently in the UK
generated the identity of melanosomes that constituted
the end product of melanocytes and melanin pigmentation
of skin. Dr Seiji and I became close friends when we both
came to Boston in 1960 to work at MGH.
Since 1959 the use of psoralens and UVA radiation have
been the subject of at least six (or perhaps more)
dermatologic conferences actively encouraged by Fitzpa-
trick and other interested investigators in photobiology to
permit the exchange of information among scientists and
clinicians. Fitzpatrick encouraged all of us to work with total
intellectual freedom to acquire new knowledge and to probe
in depth the beneficial or adverse reactions to psoralens by
living organisms (bacteria, plants, laboratory animals, and
informed human subjects with skin problems). Fitzpatrick
promoted an international meeting to allow scientists and
clinicians to evolve an avenue for better treatment of skin
diseases with pigmentary problems. He strongly postulated
that oral psoralens would constitute a better prophylactic
approach to ward off and reduce actinic damage to fair-
skinned individuals.
Since the dramatic effectiveness of psoralen photo-
chemotherapy (PUVA) in the treatment of many different
heterogenous diseases of the skin was observed, there was
a resuregence of worldwide interest in photobiology and
UVA radiation. Dermatology initiated a new era in ‘‘photo-
medicine’’ for the treatment of various skin diseases. TBF’s
book, Therapeutic Photomedicine, edited by H. Honigs-
mann and G. Stingl, provides a comprehensive review of
therapeutic photomedicine involving psoralens and UVA
radiation, as well as detailed information on the current
clinical and experimental developments in the field of
photomedicine in the treatment of psoriasis, cutaneous T
cell lymphoma, vitiligo and photodermatoses, with well-
documented sources of original papers and references. By
1988, the psoralens and high intensity UVA radiation
sources were widely used in the USA, Europe, Japan and
the rest of the world.
The use of retinoids given concurrently with PUVA
increased the efficacy of psoralens in the treatment of
severe psoriasis and other skin diseases. The Sixth
International symposium entitled ‘‘Les Psoralenes’’ was
held at Brussels in 1991. This symposium included several
leading researchers on psoralens from France, Germany,
UK, USA and some countries of Africa and Asia. It
emphasized the need for photoprotection and photochemo-
protection of human ‘‘white skin’’ against sun-induced
skin cancer from increased UVB radiation as a result of
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stratospheric ozone depletion. Unlike the US experience,
the carcinogenic risk of PUVA therapy was less emphasized
and reported in patients receiving PUVA therapy with TMP
or 5-MOP. Besides the beneficial effects of 8-MOP and UVA
photochemotherapy on psoriasis and other skin diseases,
the use of 5-MOP (Bergapten) in France was shown to be
equally as good or even better for treatment of psoriasis
and severe cases of vitiligo in India and Africa. 5-MOP was
found to be less nauseating and induced no pruritus or skin
photosensitization in patients, compared to 8-MOP.
Fitzpatrick will be remembered as a world-leading
dermatologist-scientist for his basic and clinical research
contributions. With the help of his associates, TBF contri-
buted to the treatment of vitiligo using either 8-MOP, 5-MOP,
or TMP in over 600 patients with well regulated sunlight
exposure doses for people of poor countries, where high
intensity UVA emitting lamps are not readily available for
providing PUVA therapy as practiced in the USA and
Europe. Other dermatologists may not like this approach,
but TBF strongly emphasized the precautions necessary to
prevent phototoxic skin reactions and eye problems in
patients receiving either 8-MOP, 5-MOP or TMP plus solar
UV exposure.
TBF’s contributions to decreasing skin hyperpigmenta-
tion in patients with melasma and his use of 2–3%
hydroquinine with 0.05% retinoic acid and the topical use
of broad-spectrum, high SPF sunscreens is highly recom-
mended and used by physicians all over the world to treat
patients with melasma. His contributions to treating total
depigmentation of skin in patients with disfiguring, general-
ized vitiligo with 20% monobenzyl ether of hydroquinone
(Benoquin) have been recognized for achieving ‘‘one tone
skin color’’ in children and adults. He in fact did not
recommend the use of 4-isoprophyl catechol (4-IPC), a
more effective and potent depigmenting agent than
Benoquin. 4-IPC was found to cause delayed skin sensiti-
zation reactions not only at the site of application but also at
other distal sites. He often recommended and even initiated
and conducted well-controlled clinical trials on the effec-
tiveness of sunscreens for protecting the skin of fair-skinned
individuals against actinic damage.
In this regard, I still recall the outdoor sunscreen study in
Brisbane, Australia in 1972 where TBF tested Australian,
European, and US sunscreens using paid Australian
volunteers with the approval of a regional hospital in
Brisbane. He did not hesitate to comment to the Australian
Press reporters on the poor photoprotection results of
Australian sunscreens. He learned from the results of this
study to classify skin responses of fair-skinned Australians
who participated in his study of midday sun exposure into
three main sun reactive categories: Skin Phototype I: those
who burn easily and do not tan at all; Skin Phototype II:
those who burn easily and tan with difficulty (freckled and
often red-haired individuals); and Skin Phototype III: those
who burn moderately, show immediate pigment darkening
reactions and tan moderately after about 60 minutes of
midday sun exposure. These classifications were very
helpful back in Boston in regulating and administering UV
doses for PUVA therapy in patients with psoriasis. Fitzpa-
trick’s skin phototypes I, II, III, and IV became well accepted
and popular in dermatology for phototherapy of skin
diseases and SPF evaluation of sunscreens. In 1972, the
US FDA adopted this classification for the evaluation of SPF
values of sunscreens.
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